Xuan qin seattle childrens

Murphy, MD, PhD. Salipante, MD, PhD. Melanie J. Shears, PhD. The division provides a wide range of diagnostics services in bacteriology, parasitology, mycology, mycobacteriology and molecular diagnosis. The division employs over 70 full and part time medical laboratory scientists, technicians, administrative support staff and faculty.

The Clinical Microbiology Division participates in training programs for undergraduate medical laboratory science students, Laboratory Medicine Master of Science students, medical students, clinical pathology residents and infectious diseases fellows. In addition, the division administers a CPEP-accredited postdoctoral training program in medical and public health laboratory microbiology. Please see the Education section for more information on these programs.

The clinical microbiology division supports numerous lines of research. For more information, see entries for individual faculty. Both, the sporozoite stage but particularly the elusive liver stage, are challenging to work with and have remained poorly studied. The Kappe laboratory has pioneered functional genomics studies of both sporozoites and liver stages and has thus laid the groundwork for a systems approach to their analysis.

The lab works with rodent malaria models and the human malaria parasites Plasmodium falciparum and Plasmodium vivax. Kappe have made major contributions to the field by elucidating the molecular underpinnings that regulate sporozoite infectivity for the mammalian host, factors that are critical for parasite liver infection and key parasite and host factors that are critical for intrahepatocytic liver stage growth.

He has also more recently contributed major findings in the area of host responses to liver stage infection and immunity to malaria parasite liver infection. Finally, Dr. Kappe has pioneered the design of genetically engineered, attenuated parasites for vaccination, which are tested in animal models but also in early phase human clinical studies called controlled human malaria infections.

Kappe partners with biotech for manufacturing of these attenuated vaccine strains and further clinical development. Her laboratory is particularly interested in how pathogens of global importance alter the biology of their hosts to ensure their own survival. One major effort in the Kaushansky laboratory focuses on how Plasmodium parasites, the causative agent of malaria, alter two major environments after infection: 1 the liver, which is the site of asymptomatic infection and 2 the blood brain barrier, whose breakdown causes the most severe form of malaria pathogenesis, cerebral malaria.

By identifying key host regulators of infection and pathogenesis, the Kaushansky lab has identified targeted interventions that can eliminate infection. In addition to uncovering key regulators of malaria infection, research from the Kaushansky lab has also highlighted similarities and differences between the host response to infection by the divergent parasites Toxoplasma gondii and Trypanosoma cruzi.

A better understanding of these similarities and differences could lead to broadly applicable interventions that target multiple infections with a single regimen. These tools include 1 computational tools to model host and drug responses to infection, 2 robotic systems to automate laborious laboratory tasks and, 3 the development of organs-on-chip systems in collaboration with bioengineers to study infections in vitro in a realistic environment. She collaborates broadly with scientists throughout the University of Washington and internationally.

Within the division, she has ongoing research projects with Drs. Sather, Smith, Aitchison and Rajagopal.

A list of research publications can be found here. His clinical time is split between inpatient Infectious Diseases consultations and the outpatient Infectious Diseases Clinic. He works closely with Dr. Frenkel, the Research Director and Training Grant Principal Investigator, to coordinate all aspects of research training for our fellows. Within the Division, he collaborates with Drs. Zerr and Weissman on projects related to infection prevention and antimicrobial stewardship.

Outside the Division, he collaborates with researchers at other institutions on projects related to antimicrobial stewardship in both inpatient and outpatient settings. Lingappa has been a faculty member at the University of Washington since and is currently a Professor in the Departments of Global Health and Medicine and Adjunct Professor in the Department of Pediatrics.

He received his B. He completed residency training in Pediatrics and a fellowship in Pediatric Infectious Diseases at the University of Washington. From to , he served as an officer with the US Public Health Epidemic Intelligence Service and subsequently as a medical epidemiologist at the U. Over the last decade, he has focused on conducting translational research studies to understand the sexual transmission and pathogenesis of HIV-1 infection and to identify host biological correlates for outcomes from exposure to HIV In this context he collaborates with US domestic and international researchers to integrate genomics, proteomics and microbiome laboratory studies with state-of-the-art statistical analyses to identify host factors that could be targeted for public health HIV-1 prevention interventions.

Most recently his collaborative studies have succeeded in identifying variants in the host gene, CD, as carrying significant risk of HIV-1 infection. Her research interests are in the antiretroviral management of HIV disease in children and prevention and management of complications of HIV treatment. She is also the Faculty lead for the research recruitment service for the Institute for Translational Health Sciences of the University of Washington. Frenkel, Englund and Vora. The Myler laboratory makes extensive use of genome-scale approaches, such as for genome re- sequencing, mRNA profiling RNA-seq and chromatin immunoprecipitation using sequencing ChIP-seq , to investigate the molecular mechanisms underlying transcription and regulation of gene expression during Leishmania differentiation.

We are particularly interested in elucidating the role of epigenomic histone and DNA modifications including the novel DNA base J in these processes.

For the past 20 years, we have been actively involved in structural genomics and Dr. The mission of SSGCID is to use X-ray crystallography, Cryo-electron microscopy and NMR spectroscopy to solve the structure of proteins targets in emerging and re-emerging infectious disease organisms, primarily to facilitate development of new therapeutics using structure-based drug design.

Currently, he is investigating the disease burden of a wider spectrum of respiratory viruses, establishing new endpoints, and evaluating the interaction between respiratory viral infections and antibiotic use in transplant recipients. Ogimi works closely with Drs. Her research interest is to understand virulence mechanisms of human pathogens and their interactions with the host. Her laboratory currently focuses on understanding how virulence factors of Group B Streptococcus GBS contribute to stillbirth, preterm birth and neonatal infections.

Studies from her laboratory showed that the molecular basis for GBS hemolysis is the ornithine rhamnolipid pigment and increased pigment expression exacerbates GBS virulence.

Recently, Dr. Rajagopal is also involved in efforts to understand how the Zika virus causes fetal injury during pregnancy. The goal of the research in the Rajagopal laboratory is to ultimately translate the research findings into therapeutic measures that can prevent infections during pregnancy.

I am a Pediatric Infectious Disease physician scientist who evaluates patients with complicated infections and investigates respiratory viral infections. My research focuses on understanding the key interactions of the host-viral interface in pediatric rhinovirus infections in ex-vivo human airway models. With these and future studies, I hope to identify highly impactful therapeutic targets that guide development of treatments to benefit vulnerable populations.

A guiding principle of this work is to understand infection-induced antibody responses to serve a natural prototype to guide vaccine development. The two main areas for research are HIV-1 and malaria. His HIV-1 work has helped to define how broadly neutralizing antibodies develop during infection, and his current efforts are focused on understanding the kinetics, dynamics, and evolution of B cell responses to vaccination with HIV-1 Envelope proteins.

His malaria work spans two species of malaria-causing parasites: Plasmodium falciparum and Plasmodium vivax. The major areas of this work include identification of new vaccine candidates, optimization of protective responses, and understanding how pre-existing immunity influences vaccine outcomes.

Her research focuses on innovations in medical education. Joseph D. One focus in his laboratory is to understand how Plasmodium falciparum-infected red blood cells bind to the endothelial lining of different microvascular beds and how this interaction leads to vascular inflammation and leak.

His laboratory uses a combination of field-based and laboratory studies to investigate severe malaria. Another research focus is using systems-based approaches to investigate host signaling mechanisms that regulate endothelial barrier properties and evaluating new therapeutic approaches to treat vascular injury.

A complete list of Smith lab publications can be found here. Global Health, University of Washington. Over the past 20 years the focus of the laboratory has primarily been on understanding transmission and disease progression during HIV infection. These studies have included infants, identifying changes within the infant immune system that may influence whether an exposure to HIV results in a successful infection. The long-term goal of the ongoing studies is to identify novel approaches for development of vaccines or therapeutic approaches to prevent the spread and disease complications resulting from a viral infection.

I am interested in the mechanisms of brain injury caused by infection or inflammation within the central nervous system CNS.

My undergraduate and graduate training was in basic and developmental neurosciences; understanding neural circuits and nervous system dysfunction are some of my primary scientific motivations.

As an infectious diseases clinician and translational researcher my career goal is to find ways of enhancing immune protection and limiting the detrimental effects of inflammation in neuronal circuits.

I am currently studying how the innate immune system helps control Zika virus infection, using induced neural progenitor cells which are derived from human induced pluripotent stem cells iPSCs. Using this system, we are able to derive all of the major cell types present in the developing brain, which has allowed us to identify differences in the ways that neural progenitors, neurons and glia respond to viral infection.

I am firmly committed to increasing the number and impact of underrepresented minorities and women in biomedical research and improving equity in medicine. These include malaria which is caused by Plasmodium parasites and three diverse diseases caused by related Trypanosomatid and Leishmanial parasites. His lab investigates Human immune responses to malaria vaccination and infection in order to aid vaccine development.

Berry J 2 ,. Rayar J 1 ,. Myers J 1 ,. Zerr D 5. Affiliations 3 authors 1. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Abstract No abstract provided. Free full text. Open Forum Infect Dis. Published online Dec. Author information Copyright and License information Disclaimer. Contributed by Session: Joining Europe PMC.

Tools Tools overview. ORCID article claiming. Journal list. Grant finder. External links service. Annotations submission service.